| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...626783L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0026783 |
| P932 | PMC publication ID | 3229483 |
| P698 | PubMed publication ID | 22164204 |
| P5875 | ResearchGate publication ID | 51873681 |
| P50 | author | Fabrice Carrat | Q42226814 |
| Jeremy Goldhaber-Fiebert | Q65967291 | ||
| P2093 | author name string | Shan Liu | |
| Jeremy D Goldhaber-Fiebert | |||
| Michaël Schwarzinger | |||
| P2860 | cites work | Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. | Q37342664 |
| Burden of illness of hepatitis C from a managed care organization perspective | Q40510825 | ||
| Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis | Q40739115 | ||
| An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis | Q41970506 | ||
| Treatment of patients with HCV infection with or without liver biopsy. | Q42988394 | ||
| Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs | Q42991529 | ||
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 | ||
| Exceeding the limits of liver histology markers | Q43185946 | ||
| Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population | Q43943787 | ||
| Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population | Q44324155 | ||
| Health values of patients with chronic hepatitis C infection | Q45158760 | ||
| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study | Q45737816 | ||
| Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. | Q46953851 | ||
| Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 | ||
| Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics | Q23915053 | ||
| Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C | Q24563264 | ||
| Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B | Q28251578 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Natural history of chronic hepatitis C | Q29620673 | ||
| Meta-analyses of FibroTest diagnostic value in chronic liver disease | Q33302708 | ||
| Appropriateness of liver biopsy | Q33963882 | ||
| Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. | Q34326379 | ||
| Trends in medical spending by age, 1963-2000. | Q34342102 | ||
| FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy | Q34686484 | ||
| Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 | ||
| Empirically calibrated model of hepatitis C virus infection in the United States | Q34948964 | ||
| Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. | Q35768976 | ||
| Noninvasive measures of liver fibrosis | Q36382285 | ||
| Preference-Based EQ-5D index scores for chronic conditions in the United States | Q36541277 | ||
| Health-state utilities in liver disease: a systematic review. | Q37142994 | ||
| Why, who and how should perform liver biopsy in chronic liver diseases. | Q37182969 | ||
| Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C | Q37263883 | ||
| Demographics of a large cohort of urban chronic hepatitis C patients | Q37278212 | ||
| Treating hepatitis C in the prison population is cost-saving | Q37299503 | ||
| Treatment rates in patients with chronic hepatitis C after liver biopsy. | Q50575063 | ||
| Health-state utilities and quality of life in hepatitis C patients. | Q50583400 | ||
| Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. | Q51927013 | ||
| Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. | Q51945661 | ||
| A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. | Q52010912 | ||
| Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. | Q52249518 | ||
| Liver biopsy: The best, not the gold standard | Q56833893 | ||
| Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients | Q73036086 | ||
| NIH Consensus Statement on Management of Hepatitis C: 2002 | Q75442808 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| cost-effectiveness analysis | Q1754768 | ||
| chronic hepatitis C | Q55779873 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | e26783 | |
| P577 | publication date | 2011-12-02 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients | |
| P478 | volume | 6 |
| Q59353097 | A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management |
| Q39039319 | A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models |
| Q36156172 | Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update |
| Q42048758 | Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease |
| Q36406176 | Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. |
| Q41678369 | Checkmate to liver biopsy in chronic hepatitis C? |
| Q42215056 | Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. |
| Q28488762 | Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States |
| Q28540562 | Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C |
| Q55280669 | Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. |
| Q30422586 | Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. |
| Q42227512 | Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. |
| Q38327430 | Diagnosis and Management of Hepatitis C Virus Infection |
| Q26998567 | Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature |
| Q38016312 | Finasteride and methadone use and risk of advanced hepatitis C related liver disease |
| Q36997093 | Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan |
| Q26773187 | Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. |
| Q26865956 | Non-invasive diagnosis of liver fibrosis in chronic hepatitis C |
| Q92052156 | Optimizing Implementation of Hepatitis C Birth-Cohort Screening and Treatment Strategies: Model-Based Projections |
| Q57145115 | Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence |
| Q42280296 | Recommendations for the management of hepatitis C virus infection among people who inject drugs. |
| Q35037688 | Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis |
| Q41350473 | Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses |
| Q39384475 | Tyrosine hydroxylase assay: a bioassay for aryl hydrocarbon receptor-active compounds based on tyrosine hydroxylase promoter activation |
| Q33795154 | Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK |
Search more.